Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Oregon Health and Science University National Cancer Institute (NCI) |
---|---|
Information provided by: | Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00660543 |
In this study the investigators would like to find out how a new iron containing Magnetic Resonance Imaging (MRI) contrast agent, called "ferumoxytol" can help the investigators to assess at the beginning of a therapy if it is effective or not in the treatment of a brain tumor called Glioblastoma Multiforme (GBM). For this purpose, after intravenous ferumoxytol injection, special MR scans (called: dynamic perfusion, blood-brain barrier (BBB) permeability measurement) will be performed to see the vascular changes in the brain and tumor.
Condition | Intervention | Phase |
---|---|---|
Diagnostic Imaging |
Drug: Ferumoxytol |
Phase I |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Single Group Assignment |
Official Title: | Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme |
Estimated Enrollment: | 12 |
Study Start Date: | October 2006 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients will be scanned at four time-points of their radiation/temozolomide treatment: before onset of radiation/temozolomide treatment, at 3 weeks, 6 weeks and 12 weeks following the onset of treatment. Each time-point will consist of three visits on three consecutive days. On first day: MRI with and without gadolinium (the usual MR contrast agent) infusion (0.1 mmol/kg). On second day: MRI with ferumoxytol infusion (1 mg/kg). On the third day: MRI without additional contrast agent, 24 hr post ferumoxytol infusion. There will be follow up visits 1 month and 6 months after the last ferumoxytol injection
|
Drug: Ferumoxytol
The ferumoxytol will be injected as an IV bolus of 2 mg Fe/kg over approximately 2-4 seconds at 4 ml/s flow rate, followed by a saline flush, at four time points: 2 mg/kg before, after 3 weeks of the initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Cumulative ferumoxytol dose is 8 mg/kg about the half of the iron therapy dose (2 x 510 mg). |
Patients will be scanned at four time-points of their radiation/temozolomide treatment: before onset of radiation/temozolomide treatment, at 3 weeks, 6 weeks and 12 weeks following the onset of treatment. Each time-point will consist of three visits on three consecutive days. On first day: MRI with and without gadolinium (the usual MR contrast agent) infusion (0.1 mmol/kg). On second day: MRI with ferumoxytol infusion (1 mg/kg). On the third day: MRI without additional contrast agent, 24 hr post ferumoxytol infusion. There will be follow up visits 1 month and 6 months after the last ferumoxytol injection.
The ferumoxytol molecule contains iron-oxide and other components (carbohydrate), which makes ferumoxytol safe for short and fast (bolus) injections. This new contrast agent has not shown significant side effects, even using extremely high doses in animal experiments. A total of 516 human subjects have received one or more doses of ferumoxytol. There have been 3 cases with serious side effects possibly related to the administration of ferumoxytol. Two cases of peritonitis (the inflammation of the lining the abdomen) that were possibly related and one case of anaphylaxis (serious allergic reaction) related to ferumoxytol. (Of note is that gadolinium, the standard contrast agent, carries a serious risk for persons with kidney dysfunction. This risk is the condition called nephrogenic systemic fibrosis (NSF), which causes scar tissue to develop and can, in some cases, affect internal organs and even lead to death.)
The various types of MR measurement (Perfusion, blood-brain barrier permeability, diffusion) will be evaluated or measured at each time-point, for each contrast agent. Certain regions will be described and the data will be evaluated throughout the study in an attempt to correlate changes with tumor response to therapy. The tumor volume will be evaluated by 2 radiologists, measuring the diameters of the largest areas of contrast enhancement and signal intensities will be also compared (semi-quantitatively).
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Edward A Neuwelt, MD | 503-494-5626 | neuwelte@ohsu.edu |
Contact: Nancy A Hedrick, BA | 503-494-5626 | hedrickn@ohsu.edu |
United States, Oregon | |
Oregon Health & Science University | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact: Edward A Neuwelt, MD 503-494-5626 neuwelte@ohsu.edu | |
Principal Investigator: Edward A Neuwelt, MD |
Principal Investigator: | Edward A Neuwelt, MD | Oregon Health and Science University |
Responsible Party: | Oregon Health & Science University ( Edward A. Neuwelt, MD ) |
Study ID Numbers: | OHSU-2753, NCI 26XS293 |
Study First Received: | April 10, 2008 |
Last Updated: | October 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00660543 |
Health Authority: | United States: Food and Drug Administration |
ferumoxytol |
Neuroectodermal Tumors Glioblastoma Glioblastoma multiforme Astrocytoma Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Glioma Temozolomide Iron Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial |